Immune Therapeutics, Inc. Announces Exclusive Agreement for Sale of Lodonal in Kenya Valued at Over $31 Million

Immune Therapeutics, Inc. Announces Exclusive Agreement for Sale of Lodonal in Kenya Valued at Over $31 Million

ORLANDO, Fla., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a specialty pharmaceutical company focused on developing and commercializing Lodonal™, its patented, affordable, non-toxic therapy for the management of cancer, HIV, autoimmune diseases and other inflammatory conditions, today announced that it has entered into an exclusive agreement with Kenya-based Omaera Pharmaceuticals, Ltd. for the sale and distribution of Lodonal™, valued at a minimum of $31 million in revenues over three years.

Read More
IMMUNE THERAPEUTICS, INC. APPOINTS JOHN H. ABELES, M.D. AS CHAIRMAN AND CEO OF COMPANY’S SUBSIDIARY, CYTOCOM, INC. AND AS SENIOR ADVISER TO IMMUNE THERAPEUTICS, INC.

IMMUNE THERAPEUTICS, INC. APPOINTS JOHN H. ABELES, M.D. AS CHAIRMAN AND CEO OF COMPANY’S SUBSIDIARY, CYTOCOM, INC. AND AS SENIOR ADVISER TO IMMUNE THERAPEUTICS, INC.

Appointment of Experienced Biotech Industry Veteran and Wall Street Executive to Spearhead Cytocom’s Future Growth and Expansion ORLANDO, Florida, August...

Read More
Immune Therapeutics Signs Memorandum of Understanding for Distribution of Lodonal™ in Côte d’Ivoire and acquires COPP for Côte d’Ivoire; Company Plans for Approval of Lodonal in Côte d’Ivoire in 2017

Immune Therapeutics Signs Memorandum of Understanding for Distribution of Lodonal™ in Côte d’Ivoire and acquires COPP for Côte d’Ivoire; Company Plans for Approval of Lodonal in Côte d’Ivoire in 2017

ORLANDO, Fla., May 31, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc.(OTCQB:IMUN), a specialty pharmaceutical company focused on developing and commercializing our novel patented, affordable, non-toxic therapy for the management of cancer, HIV, autoimmune diseases, and other inflammatory conditions, today announced that it has signed a Memorandum of Understanding (“MOU”) for the distribution of its patented Lodonal™ in Côte d’Ivoire (the Ivory Coast).

Read More